Title:
ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測
Document Type and Number:
Japanese Patent JP6581244
Kind Code:
B2
Abstract:
This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.
More Like This:
| WO/2012/122379 | MICROFLUIDIC CYTOCHEMICAL STAINING SYSTEM |
| WO/1997/016540 | CHITIN SYNTHASE 1 |
| JP2005503101 | Genes encoding membrane-binding proteins that bind mammalian DNA and their use |
Inventors:
Alan smith
Paul West
Jessica Palmer
Paul West
Jessica Palmer
Application Number:
JP2018091559A
Publication Date:
September 25, 2019
Filing Date:
May 10, 2018
Export Citation:
Assignee:
Stemina Biomarker Discovery, Inc.
International Classes:
C12Q1/02; G01N27/62; G01N33/68
Foreign References:
| WO2011119637A1 |
Other References:
Toxicology and Applied Pharmacology,2010年,Vol.247,pp.18-27
Birth Defects Research (Part B),2013年10月,Vol.98,pp.343-363
Birth Defects Research (Part B),2013年10月,Vol.98,pp.343-363
Attorney, Agent or Firm:
Atsushi Aoki
Shinji Mitsuhashi
Yoichi Watanabe
Masaru Nakajima
Ryotaro Takei
Shinji Mitsuhashi
Yoichi Watanabe
Masaru Nakajima
Ryotaro Takei